Egle Therapeutics has received €9.3 million in non-dilutive funding from France 2030's "Innovations in Biotherapies and Bioproduction" initiative to accelerate development of its lead immuno-oncology candidate EGL-001.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.